Aprogen Biologics에이프로젠바이오로직스
003060 · KOSPI · ₩003060 · 에이프로젠바이오로직스
₩1,335▼ ₩45 (3.26%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | −27.3% | −36.9% | −11.2% | −13.4% | 41.9% | 45.0% |
| Operating margin | −67.0% | −82.4% | −78.4% | −65.8% | −8.3% | −6.7% |
| Net margin | −90.9% | −232.6% | −155.8% | −135.4% | 12.0% | 14.3% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +17.7% | +8.7% | −22.9% | +34.0% | +15.4% | — |
| Operating income growth | +4.3% | −14.3% | +8.1% | −958.5% | −42.9% | — |
| Net income growth | +54.0% | −62.3% | +11.2% | −1,609.1% | −3.3% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −39.0% | −58.1% | −28.1% | −29.9% | 1.7% | 1.6% |
| Return on assets | −19.6% | −28.6% | −17.8% | −18.2% | 0.9% | 1.5% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 104.9% | 111.5% | 56.1% | 59.9% | 34.6% | 2.9% |
| Net debt to equity | 62.6% | 66.0% | 32.6% | 41.0% | 22.0% | −5.5% |
| Current ratio | 56.9% | 67.4% | 78.1% | 53.7% | 149.3% | 3,740.9% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Aprogen Biologics / 에이프로젠바이오로직스 / 003060 / KRX:003060
Source: KRX statistical information